Evidence map›Paper›PMID 29318594›Full record

ArticleBritish journal of pharmacology2018

Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Jia Liu, Hermann Bihler, Carlos M Farinha, Nikhil T Awatade, Ana M Romão, Dayna Mercadante, Yi Cheng, Isaac Musisi, Walailak Jantarajit, Yiting Wang and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causingProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Comparison of the Effect of CFTR ModulatorsJournal of clinical medicine · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Molecular basis of cystic fibrosis: from bench to bedside.Annals of translational medicine · 2018
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Jia LiuSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Hermann BihlerCystic Fibrosis Foundation Therapeutics, Lexington, MA, USA.ORCID 0000-0002-8167-1548
Carlos M FarinhaFaculty of Sciences, BioISI - Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal.ORCID 0000-0002-5467-1710
Nikhil T AwatadeFaculty of Sciences, BioISI - Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal.ORCID 0000-0003-1560-7991
Ana M RomãoFaculty of Sciences, BioISI - Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal.
Dayna MercadanteCystic Fibrosis Foundation Therapeutics, Lexington, MA, USA.
Yi ChengCystic Fibrosis Foundation Therapeutics, Lexington, MA, USA.
Isaac MusisiCystic Fibrosis Foundation Therapeutics, Lexington, MA, USA.
Walailak JantarajitSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.ORCID 0000-0003-1308-3987
Yiting WangSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Zhiwei CaiSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Margarida D AmaralFaculty of Sciences, BioISI - Biosystems and Integrative Sciences Institute, University of Lisboa, Lisboa, Portugal.ORCID 0000-0002-0828-8630
Martin MenseCystic Fibrosis Foundation Therapeutics, Lexington, MA, USA.ORCID 0000-0003-0280-9789
David N SheppardSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.ORCID 0000-0001-5533-9130
Cystic Fibrosis Foundation · USUniversity of Bristol · GBUniversity of Lisbon · PTMahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeRescue of F508del-cystic fibrosis (CF) transmembrane conductance regulator (CFTR), the most common CF mutation, requires small molecules that overcome protein processing, stability and channel gating defects. Here, we investigate F508del-CFTR rescue by CFFT-004, a small molecule designed to independently correct protein processing and channel gating defects. EXPERIMENTAL APPROACH: Using CFTR-expressing recombinant cells and CF patient-derived bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating and stability with the patch-clamp and Ussing chamber techniques. KEY

resultsChronic treatment with CFFT-004 improved modestly F508del-CFTR processing, but not its plasma membrane stability. By contrast, CFFT-004 rescued F508del-CFTR channel gating better than C18, an analogue of the clinically used CFTR corrector lumacaftor. Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR channel gating. However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with a comparable mechanism of CFTR dysfunction as F508del-CFTR. To investigate the mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations. Potentiation by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the revertant mutation G550E. These data suggest that correction, but not potentiation, by CFFT-004 might involve nucleotide-binding domain 1 of CFTR. CONCLUSIONS AND IMPLICATIONS: CFFT-004 is a dual-acting small molecule with independent corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells and native airway epithelia. The limited efficacy and potency of CFFT-004 suggests that combinations of small molecules targeting different defects in F508del-CFTR might be a more effective therapeutic strategy than a single agent.

Indexed as

AnimalsCell LineCell MembraneCells, CulturedCricetinaeCystic Fibrosis Transmembrane Conductance RegulatorEpithelial CellsHumansIon Channel GatingMiceProtein Processing, Post-TranslationalProtein StabilityCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID29318594
PMCPMC5843712
OpenAlexW2783284343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.